Complete Cost Breakdown: Wegovy vs Mounjaro Comparison
Transparent Pricing: 1.7mg Wegovy to Mounjaro Cost Analysis
When comparing 1.7mg Wegovy to Mounjaro, hidden fees from online pharmacies create confusion and frustration. EverydayMeds eliminates this uncertainty with complete price transparency for both treatments. Our 1.7mg Wegovy costs £139.99 - this single price includes your clinical assessment, prescriber review, the prescription itself, the medication, and next-day cold-chain delivery. Unlike competitors who charge separate consultation fees, prescription charges, or administration costs, you pay exactly what you see.
Many patients switching from 1.7mg Wegovy to Mounjaro discover unexpected charges elsewhere - consultation fees ranging from £20-50, prescription charges, or delivery premiums. At EverydayMeds, both Wegovy and Mounjaro follow identical transparent pricing structures. Whether you choose our Consistency 1.7mg bundle (two pens for £309.99) or explore Mounjaro options, every price displayed represents your total investment. This transparency allows genuine treatment comparison based on clinical factors, not billing surprises.
Value Comparison: 1.7mg Wegovy to Mounjaro Pricing Structure
Understanding true value when considering 1.7mg Wegovy to Mounjaro requires examining complete treatment costs, not just medication prices. Our 1.7mg Wegovy represents weeks 13-16 of your dose escalation journey, priced at £139.99 with new customer code FIRST40 applied at checkout. For treatment continuity, our Elevate Duo (1.7mg plus 2.4mg maintenance dose) costs £369.99, providing a seamless transition to your target maintenance level without multiple orders.
Returning customers switching from 1.7mg Wegovy to Mounjaro can apply code DOSE25 for optimal pricing across both treatment options. Both medications require identical clinical assessment processes, prescriber review timelines, and cold-chain delivery methods. This pricing parity ensures your treatment choice focuses on clinical considerations - mechanism of action, storage requirements, and individual response patterns - rather than cost variations that create artificial treatment barriers.
Clinical Evidence: 1.7mg Wegovy to Mounjaro Trial Comparison
When evaluating 1.7mg Wegovy to Mounjaro switches, clinical trial evidence provides essential context for informed decisions. Wegovy's STEP trials demonstrated that patients taking semaglutide alongside diet and exercise achieved average weight loss of approximately 15% at 68 weeks in STEP 1. The STEP 5 trial showed sustained weight loss of approximately 15.2% maintained over 2 years with continued treatment.
Mounjaro's tirzepatide trials used different study designs, populations, and endpoints, making direct comparison inappropriate. Both treatments are prescription-only medicines requiring clinical assessment to determine suitability. Your prescriber can evaluate which mechanism - Wegovy's GLP-1 receptor agonism or Mounjaro's dual GIP+GLP-1 approach - may better align with your individual circumstances and treatment goals.
Mechanism Differences: 1.7mg Wegovy to Mounjaro Action Profiles
Understanding how 1.7mg Wegovy compares to Mounjaro requires examining their distinct mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your natural fullness hormone, reducing appetite and promoting satiety after smaller meals. This single-pathway approach may help reduce food cravings by working on brain appetite centres. Mounjaro utilises tirzepatide, a dual agonist targeting both GIP and GLP-1 receptors simultaneously, potentially affecting glucose regulation and appetite through complementary pathways. Both treatments must be used alongside a reduced-calorie diet and increased physical activity for optimal effectiveness.
Streamlined Ordering: 1.7mg Wegovy to Mounjaro Assessment Process
Switching from 1.7mg Wegovy to Mounjaro through EverydayMeds follows our identical streamlined process for both treatments. Complete our 3-minute online clinical assessment covering your medical history, current medications, and treatment goals. Our prescribers review your assessment within 3 working days (express 24-hour service available), determining suitability for your chosen treatment. Once approved, your medication ships via next-day delivery using temperature-controlled cold-chain logistics, ensuring product integrity. This standardised process applies whether you're continuing with 1.7mg Wegovy or exploring Mounjaro alternatives, maintaining consistency and reducing treatment transition complexity.
Storage Advantages: 1.7mg Wegovy to Mounjaro Practical Considerations
Storage requirements present a key practical difference when comparing 1.7mg Wegovy to Mounjaro options. Wegovy pens maintain potency for 6 weeks at room temperature below 30°C once removed from refrigeration, whilst Mounjaro requires refrigeration return within 21 days. This storage advantage makes Wegovy particularly suitable for frequent travellers, shift workers, or those with limited refrigeration access. Both treatments arrive requiring initial refrigerated storage at 2-8°C until first use. Your 1.7mg Wegovy utilises Novo Nordisk's FlexTouch pen system, designed for weekly subcutaneous injection as part of the mandatory dose escalation protocol from 0.25mg through to 2.4mg maintenance levels.
Treatment Transition: 1.7mg Wegovy to Mounjaro Switch Considerations
Patients considering switching from 1.7mg Wegovy to Mounjaro require careful clinical guidance to ensure treatment continuity and safety. The 1.7mg Wegovy dose represents your penultimate escalation step before reaching 2.4mg maintenance, suggesting established treatment tolerance and emerging effectiveness patterns. Switching treatments at this advanced stage requires prescriber assessment of your response profile, any side effects experienced, and treatment goals. Both medications are prescription-only medicines manufactured to identical pharmaceutical standards and subject to MHRA regulation.
Geographic and lifestyle factors may influence your 1.7mg Wegovy to Mounjaro decision-making process. Consider storage requirements, injection frequency (both weekly), and pen system preferences when discussing options with your prescriber. EverydayMeds maintains identical service standards for both treatments, ensuring consistent clinical assessment quality, delivery timelines, and ongoing support regardless of your final treatment choice.
Complete Treatment Investment: 1.7mg Wegovy to Mounjaro Final Decision
Making your final 1.7mg Wegovy to Mounjaro choice requires complete cost transparency and clinical understanding we provide at EverydayMeds. Your 1.7mg Wegovy at £139.99 represents total treatment investment, whilst Mounjaro follows identical transparent pricing principles. New customers apply code FIRST40, returning patients use DOSE25 - both codes work for either treatment option. Visit https://everydaymeds.co.uk/products/wegovy-1-7mg to begin your clinical assessment or continue your current treatment journey. Both Wegovy and Mounjaro remain available through our GPhC-registered pharmacy (#9012878), ensuring consistent quality, clinical oversight, and delivery reliability. Your treatment choice deserves complete transparency, comprehensive support, and genuine clinical expertise throughout your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
